Archives
American Kidney Fund’s Undiagnosed Causes Of Kidney Disease Initiative
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
American Kidney Fund’s Undiagnosed Causes Of Kidney Disease Initiative
Background
- Patients that do not have a definitive cause of their kidney disease may face many barriers or receive suboptimal care during their medical journey. The American Kidney Fund’s (AKF) Undiagnosed Causes of Kidney Disease Initiative seeks to improve the understanding of how undiagnosed or misdiagnosed causes of kidney disease directly impact patient care and outcomes, as well as gain insights of the patient journey to a rare kidney disease diagnosis.
- From a survey conducted by the AKF, the most commonly cited known cause of kidney disease was a history of high blood pressure, followed by history of diabetes. Only 6% had a diagnosed rare disease, while 27% had no known cause. Other cited causes included medications and cancer.
- This webinar with the AKF will help promote meaningful, systemic change to ensure that patients with kidney disease get the diagnosis they need and the care they deserve. Overcoming barriers to identifying the root cause of kidney disease for currently unknown reasons, will not be accomplished quickly. However, thoughtful, dedicated collaboration among the kidney care community can result in steady progress toward expanding access to genetic testing, reducing systemic inequalities, engaging providers, and empowering patients.
- Insight into the American Kidney Fund’s the Undiagnosed Causes of Kidney Disease (UCKD) initiative.
- Preliminary data from survey conducted with HCPs to better understand when and how patients are being diagnosed (eg Primary Care, Referred to Nephrology, Etc).
- Tools and action steps for healthcare providers to learn more, such as the Unknown Causes of Kidney Disease Project roadmap to promote meaningful, systemic change to ensure that patients with kidney disease get the diagnosis they need and the care they deserve.
Featuring
Michael Spigler
American Kidney Fund*
Mr Spigler has served as vice president of Patient Services and Kidney Disease Education for the American Kidney Fund (AKF) since July 2015. He oversees a spectrum of programs and services: prevention activities, top-rated health educational resources, and direct financial assistance that enables kidney patients to access lifesaving medical care, including dialysis and transplantation. Mr Spigler has more than 20 years of experience in creating and managing health education programs for a multitude of chronic health conditions, including kidney disease, cancer, food allergies and anxiety disorders. In 2011, he was among the first group of health educators named Master Certified Health Education Specialists by the National Commission for Health Education Credentialing.
Max Hyams, PharmD, RPh
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Max Hyams, PharmD, RPh, is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization (OPDC) covering New Jersey. He earned his Doctorate of Pharmacy from Albany College of Pharmacy and Health Sciences in Albany, New York. Prior to joining Otsuka, he was a Global Pharmacovigilance Case Processor in Specialty Medicine at Bayer, working closely with colleagues in Brazil and Germany. Prior to that, he was a Pharmacy Manager for CVS, working in the highest volume, 24-hour stores in Northern New Jersey, and has experience working for an independent pharmacy specializing in fertility medications. He is currently licensed as a pharmacist in New Jersey and resides in Hoboken, New Jersey.
*Michael Spigler is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Max Hyams is an employee of OPDC.
